Over the years, Teva has grown significantly across the globe through numerous successful acquisitions that integrated and enhanced our expertise in innovative and generic medicines with branded medicines, as well as new therapeutic areas and markets.

Today, we are among the top 15 global pharmaceutical companies and a world leader in generic and specialty medicines. We are constantly investing in healthcare options that are fit for the future, such as new technologies, innovative devices and a fresh approach to services.

To this end, we are partnering with technology, digital and e-health companies to expand our reach in the healthcare arena and ensure we remain at the cutting-edge of technology to ultimately develop innovative, effective healthcare options for our patients.

A number of our innovative healthcare initiatives were recently featured at the NHS Health and Care Innovation Expo in Manchester in September 2019, where Teva UK Limited was a Digital Health Zone Partner. The Expo is a highly significant annual event in the NHS calendar, uniting individuals across all health and social care sectors including NHS leaders, commissioners, clinicians, voluntary sector partners and many more. The event has the overall purpose of promoting renewal, change and improvement within our health and social care sectors.

Teva UK Limited hosted a Digital Transformation Zone at the Expo, where a number of our initiatives, some in collaboration with healthcare partners, were discussed:

  • The multiple chronic conditions index and its potential impact on healthcare policy
  • The benefits of digital inhaler technologies
  • A focus on the burden of migraine in the UK
  • The Life Effects initiative, a patient support programme

In addition, Teva participated in a panel discussion on the main stage at the Expo to discuss the impact of a behavioural change programme for multiple chronic conditions.

Click on the wheel below to find out more about each initiative.